Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The...

Area of Science:

• Oncology
• Thoracic Oncology
• Radiation Oncology

Background:

• Standard treatment for extensive-stage small cell lung cancer (ES-SCLC) involves chemoimmunotherapy followed by immunotherapy maintenance.
• Limited data exist on the efficacy and safety of adding consolidative thoracic radiotherapy (TRT) to this regimen.

Purpose of the Study:

• To evaluate the safety and efficacy of consolidative TRT combined with immunotherapy maintenance in ES-SCLC patients.
• To determine the impact on overall survival (OS) and progression-free survival (PFS).

Main Methods:

• A multicenter, open-label, phase 2 randomized clinical trial (NCT04462276) was conducted.
• Patients with ES-SCLC achieving at least stable disease after induction chemoimmunotherapy were randomized (1:1) to atezolizumab maintenance with or without TRT.
• The primary outcome was OS.

Main Results:

• Recruitment was prematurely terminated due to safety concerns.
• Median OS was numerically shorter in the TRT plus atezolizumab arm compared to atezolizumab alone (6.7 vs 13.4 months).
• Severe adverse events (SAEs) and fatal outcomes were significantly higher in the TRT arm (61.3% vs 18.2% for SAEs; 19.4% vs 3.0% for fatal outcomes).
• Infections and respiratory disorders were the predominant SAEs, potentially linked to radiation-induced lymphocyte depletion.

Conclusions:

• Consolidative TRT combined with immunotherapy maintenance in unselected ES-SCLC patients increased toxicity without improving survival.
• Further investigation is needed to identify patient subgroups who might benefit from TRT with acceptable risk.
• Cautious patient selection is crucial for future trials exploring TRT in ES-SCLC.